A research project has been launched in Switzerland that aims to improve prevention and management of diabetes-related kidney disease.
Kidney disease is a common complication of diabetes as high levels of glucose (sugar) in the blood can damage the tiny filters in the kidneys.
There is currently no effective way to prevent or cure diabetes-related kidney disease, and the condition is the leading cause of kidney related deaths.
BEAt-DKD (Biomarker Enterprise to Attack Diabetic Kidney Disease) is a new five-year project with a budget of £25 million (28.9 million Euros), funded by the Innovative Medicines Initiative (IMI), made up of leading experts from 21 academic institutions, member companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Juvenile Diabetes Research Foundation (JDRF) and the state of Switzerland.
The aim of the project will be to identify what causes diabetes-related kidney disease, as well how the condition progresses and possible future treatments.
Maria F Gomez, Project Coordinator, and Professor at Lund University, Sweden, said: “We are very excited to have gathered so many brilliant and truly dedicated investigators, impressive materials and innovative techniques in this unprecedented joint effort to make a real difference for people with diabetes-related kidney disease.”
Dennis Andress, Project Leader from pharmaceutical company Abbvie, added: “This project represents one of the largest and most complete analyses of clinical data for identifying potential biomarkers for diabetes-related kidney disease and it will establish a new paradigm for precision medicine in the management of diabetes-related kidney disease.”
Find out more here
Chronic kidney disease on the NHS website